Prognostic factors for efficacy of Ipilimumab used after anti-PD1 and/ or BRAF plus MEK inhibitors in melanoma patients: An Italian melanoma intergroup studyR. Marconcini, A. Nuzzo, S. Manacorda,F. de Rosa,P. Fava,C. Astrua, L. A. Di Guardo,A. Raimondi,S. L. Stucci,A. Todisco,A. Cortellini,M. Bersanelli,O. Nigro,M. Palla,G. Palmieri,A. FalconeANNALS OF ONCOLOGY（2019）引用 1|浏览57暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
